The Council of the European Union is gearing up to speak with one voice at the upcoming sixty-ninth session of the United Nations Commission on Narcotic Drugs (CND) in March 2026. Its goal? To support international control on three emerging psychoactive substances flagged for health and social risks. This move is poised to impact EU Member States’ drug legislation, drug enforcement authorities, public health bodies, and the burgeoning synthetic opioid and cannabinoid markets, sparking reactions across these groups.
The information comes from a Council Decision proposal dated December 18, 2025, under reference COM(2025)777, issued by the EU’s Home Affairs Directorate. The document outlines the EU's official stance for the CND session, at which voting members—including 14 Member States—will express a unified position.
This document is a formal legislative proposal intended to bind EU Member States that hold votes in the CND to a joint position. It contains detailed policy plans endorsing the scheduling of three substances: N-pyrrolidino isotonitazene and N-desethyl etonitazene (both synthetic opioids recommended for Schedule I), and MDMB-FUBINACA (a synthetic cannabinoid proposed for Schedule II), based on WHO scientific evaluations and evidence gathered by the EU Drugs Agency (EUDA). The proposal leverages the Union’s exclusive competence on drug control under Articles 83 and 218 TFEU, reinforcing the link between UN scheduling and EU drug laws.
The policy orientation favors strengthening international drug control via tighter restrictions on new psychoactive substances, thus extending the scope of EU drug legislation. This reinforces the EU's ability to act jointly in the international arena, although it reflects a strengthening of supranational competence in drug scheduling at the expense of purely national decision-making.
Key stakeholder impacts include enhanced enforcement tools for EU regulatory bodies and national authorities tasked with drug control, potential compliance costs and operational burdens for EU producers and distributors in the pharmaceutical and chemical sectors, increased protections for EU consumers wary of dangerous synthetic drugs, and regulatory alignment pressures on EU civil society advocating for public health.
Institutionally, this marks a preparatory step leading into the March 2026 session of the CND, where 14 EU Member States will exercise their votes in alignment with the Council Decision. Attention now shifts to the UN Commission on Narcotic Drugs itself, which will decide whether to adopt these changes, influencing EU and global drug policy frameworks thereafter.